Last reviewed · How we verify
NCT04139031
Corrected Flow Time in the Carotid Artery as a Predictor of Fluid Responsiveness in Mechanically Ventilated Patients With Low Tidal Volume in the Intensive Care Unit
trial testing Ultrasonographic measurement of corrected flow time in carotid artery in Hypovolemic in 37 participants. Completed in 25 September 2020.
25 September 2020
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 5 November 2019 |
| Primary completion | 25 September 2020 |
| Estimated completion | 25 September 2020 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Ultrasonographic measurement of corrected flow time in carotid artery
Conditions studied
- Hypovolemic — all drugs for Hypovolemic →
Sponsor
Yonsei University
Who can join
19 and older, any sex, with Hypovolemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate predictability of carotid corrected flow time for fluid responsiveness in mechanically ventilated patients with low tidal volume in the intensive care unit.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ability of Carotid Corrected Flow Time to Predict Fluid Responsiveness in Patients Mechanically Ventilated Using Low Tidal Volume after Surgery.
Jung S, Kim J, Na S, Nam WS, et al · · 2021 · cited 14× · PMID 34204523 · DOI 10.3390/jcm10122676
Verify or expand the search:
- PubMed search for NCT04139031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypovolemic
Currently open trials in the same condition.
- NCT05931601 — Early Initiated Vasopressor Therapy in the Emergency Department · Phase 3 · recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04139031 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04139031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing